$366 Million is the total value of Flagship Pioneering Inc.'s 9 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MCRB | New | SERES THERAPEUTICS INC | $155,873,000 | – | 12,682,876 | +100.0% | 42.59% | – |
SYRS | New | SYROS PHARMACEUTICALS INC | $66,668,000 | – | 4,806,656 | +100.0% | 18.22% | – |
AGIO | New | AGIOS PHARMACEUTICALS INC | $50,991,000 | – | 965,369 | +100.0% | 13.93% | – |
EDIT | New | EDITAS MEDICINE INC | $46,578,000 | – | 3,455,316 | +100.0% | 12.73% | – |
SELB | New | SELECTA BIOSCIENCES INC | $23,539,000 | – | 1,651,862 | +100.0% | 6.43% | – |
TTOO | New | T2 BIOSYSTEMS INC | $15,756,000 | – | 2,176,167 | +100.0% | 4.30% | – |
EBIO | New | ELEVEN BIOTHERAPEUTICS INC | $6,594,000 | – | 2,354,710 | +100.0% | 1.80% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
MODERNA INC | 20 | Q3 2023 | 76.9% |
EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
Axcella Health Inc | 17 | Q2 2023 | 3.5% |
KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
4 | 2024-02-14 |
13F-HR | 2023-11-14 |
4 | 2023-09-15 |
4 | 2023-08-15 |
13F-HR | 2023-08-14 |
4 | 2023-07-13 |
13F-HR | 2023-05-15 |
4 | 2023-02-27 |
13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.